In its second deal in two months to bolster its immuno-oncology prospects, Baxalta has entered into a collaboration with Precision BioSciences to utilize the latter’s proprietary ARCUS genome editing technology to develop an allogeneic chimeric antigen receptor-T cell (CAR T) therapeutic pipeline directed towards areas of unmet need in multiple cancers. The two companies will develop CAR-T therapies for up to six targets, the first of which is expected to enter clinical development in late 2017.